On The Pen™ GLP-1 News

The host of On The Pen interviews Dr. Ian Ellis, a board-certified emergency physician who runs his own clinic. Ellis argues that the standard GLP-1 dosing ladder keeps raising a person's drug level even when the number on the pen stays the same.

1. 0:00 Why most GLP-1 users are never on the same dose twice
2. 1:55 Dr. Ian's background: trainer, nutritionist, ER physician
3. 4:00 His obsessive relationship with food and body composition
4. 7:45 The two impossible choices: obsession or obesity
5. 10:12 How medical school destroyed his health
6. 10:25 A colleague mentions Ozempic for the first time
7. 11:35 His first dose and what real satiety feels
8. 13:00 Why the same dose felt worse every single week

• Doses mentioned: 2.5 mg, 5 mg and 15 mg
• Weight loss mentioned: 30 lb
• Side effects mentioned: nausea, diarrhea, muscle loss and low appetite
• Who is speaking: News or media

In this video, Dave, who describes himself as a heavier man and a type 2 diabetic, gives an update after one week on Mounjaro at the 2.5 mg dose. He says he started the series because he found few videos from men covering what to expect.

1. 0:00 Introduction
2. 2:46 How it works
3. 4:15 Food, protein and eating
4. 5:01 Dose change

• Doses mentioned: 2.5 mg
• Who is speaking: News or media

A news or media piece demonstrates the Zepbound injection, step by step. It has no captions we could read, so this is drawn from its title and description.

• Who is speaking: News or media

A news or media piece talks about Mounjaro doses and moving up, mentioning 5 mg. It has no captions we could read, so this is drawn from its title and description.

• Doses mentioned: 5 mg
• Who is speaking: News or media

A news or media piece explains how tirzepatide works and what the evidence says. It has no captions we could read, so this is drawn from its title and description.

• Who is speaking: News or media

In this personal update, the host of On The Pen says he is a type 2 diabetic who has struggled to respond to GLP-1 medications the way many others do.

1. 0:00 Personal update on weight loss
2. 1:08 Medication history and issues
3. 4:07 Lifestyle changes and challenges
4. 5:57 Adopting a ketogenic diet
5. 7:04 New supplements and programs
6. 8:25 Keto breathalyzer monitoring
7. 12:36 Future outlook and community

• Doses mentioned: 5 mg, 7.5 mg, 12.5 mg and 15 mg
• Who is speaking: News or media

In this episode of the Weekly Dose podcast from On The Pen, host Dave Nap reports on a ClinicalTrials.gov listing that he says points to a pre-approval expanded access program for retatrutide from Eli Lilly.

1. 1:23 Injection technique
2. 5:14 The trials
3. 13:54 Cost and insurance
4. 17:58 Wrapping up

• Doses mentioned: 15 mg
• Side effects mentioned: fatigue
• Who is speaking: News or media

A news or media piece looks at what Mounjaro costs and how coverage works. It has no captions we could read, so this is drawn from its title and description.

• Who is speaking: News or media

A news or media piece explains how a GLP-1 works and what the evidence says. Also covers the trials.

• Who is speaking: News or media

The host of On The Pen GLP-1 News reacts to Eli Lilly's new phase three top-line data for retatrutide from the Triumph 1 study.

1. 0:00 Introduction to study data
2. 2:16 Phase 3 clinical trial results
3. 3:55 Analyzing real-world efficacy
4. 5:42 Tolerability and side effects
5. 7:37 Lilly's broad strategy
6. 8:45 Legal and regulatory outlook
7. 10:53 Market positioning and future

• Doses mentioned: 15 mg
• Side effects mentioned: nausea, vomiting, constipation, diarrhea and bloating
• Prices mentioned: $10,000 a month
• Who is speaking: News or media

A news or media piece talks about Wegovy doses and moving up. It has no captions we could read, so this is drawn from its title and description.

• Who is speaking: News or media

According to the video, the host answers two questions about Zepbound, the weight loss version of Mounjaro: what it will cost and whether a copay assistance coupon will exist.

• Who is speaking: News or media

A news or media piece explains how retatrutide works and what the evidence says. It has no captions we could read, so this is drawn from its title and description.

• Who is speaking: News or media

In this episode of the Weekly Dose podcast from On The Pen, host Dave Knapp explains two separate federal programs that he says are often confused: the Medicare GLP-1 Bridge Program and the Balance Model.

1. 0:00 Medicare GLP-1 Coverage Hype and Confusion
2. 1:09 Show Intro and Sponsor Message
3. 2:19 The $50 GLP-1 Medicare Claim Explained
4. 3:05 Bridge vs BALANCE Programs
5. 3:31 Why Medicare Cannot Cover Obesity Drugs Yet
6. 4:55 The Medicare GLP-1 Bridge Program (2026)
7. 7:01 What Patients Will Pay and the $50 Copay
8. 9:26 Which GLP-1 Drugs Are Included

• Prices mentioned: $245 a month and $50 a month
• Who is speaking: News or media

A news or media piece looks at the program. Also covers the trials.

• Who is speaking: News or media

This weekly news episode from On the Pen covers regulatory and scientific developments affecting compounded semaglutide and tirzepatide.

1. 0:00 Massive compound shakeup
2. 0:43 Why compound users need this
3. 1:25 Sponsor, Shed obesity care
4. 2:11 Breaking news changed everything
5. 2:28 OTP semaglutide exclusive
6. 3:28 DDC list explained
7. 4:24 Novo’s lab findings
8. 9:57 302% dose shocker

• Doses mentioned: 0.25 mg and 2.5 mg
• Who is speaking: News or media

According to the video, host Dave Nap of the On The Pen channel walks through the 2026 Zepbound savings card details from Lilly. He says there are again two tracks, and both require commercial insurance, such as employer or marketplace coverage.

1. 0:00 2026 savings card updates
2. 1:11 No coverage track
3. 4:02 With coverage track
4. 7:56 Summary and key takeaways

• Doses mentioned: 2.5 mg, 5 mg and 7.5 mg
• Prices mentioned: $25 a month, $600 a year and $30,000 a year
• Who is speaking: News or media

Dave, host of On The Pen GLP-1 News, reviews remarks about the Mounjaro copay card made by Eli Lilly CFO Anat Ashkenazi at a JP Morgan conference fireside chat on January 10.

1. 0:00 Welcome and update
2. 0:26 Eli Lilly CFO conference
3. 2:50 Coupon changes impact
4. 6:33 Options for patients
5. 9:10 Closing and call to action

• Who is speaking: News or media

This episode of On The Pen is an interview with Sabina Hemmi, who attended the most recent court hearing in Eli Lilly's lawsuit against Mochi Health.

1. 0:00 Case background and updates
2. 1:38 Legal arguments and claims
3. 5:50 Conflicts of interest
4. 9:03 Vertical integration concerns
5. 13:22 Standard for dismissal
6. 17:12 Potential industry ripple effects
7. 21:51 FDA and legislative threats
8. 26:43 Looking ahead to future access

• Who is speaking: News or media

According to the video, Eli Lilly has filed lawsuits in district court in California against four telehealth companies that offer compounded tirzepatide: Mochi Health, Fella and Delilah Health, Willow Health Services, and Henry Meds.

1. 0:00 Eli Lilly lawsuits update
2. 1:31 Allegations and safety issues
3. 3:16 Compounding market battle
4. 5:31 Industry impact and next steps

• Who is speaking: News or media

The speaker says they strongly support access to GLP-1 medications, and acknowledges that people who need them are having a hard time getting them. They say they have not talked much about compounded versions on their channel but feel the debate deserves attention.

• Who is speaking: News or media

In this live stream from January 5, 2026, host Dave Nap and co-host Ham Bone cover the day's main story: Novo Nordisk launching oral Wegovy as the first GLP-1 pill for obesity.

1. 0:00 Welcome to On The Pen Live
2. 0:45 What dropped today and why it matters
3. 2:10 Oral Wegovy officially launches
4. 3:35 Why this is not just another product launch
5. 5:10 Who this pill is for and who it leaves out
6. 7:40 Injection hesitation and access barriers
7. 10:05 How oral Wegovy actually works
8. 13:20 Weight loss expectations vs injections

• Doses mentioned: 1.5 mg, 4 mg, 9 mg and 25 mg
• Side effects mentioned: fatigue and hair loss
• Prices mentioned: $80 a month, $299 a month and $300 a month
• Who is speaking: News or media

In this video, host Dave Knap of On The Pen addresses two questions he says he gets asked often: whether Zepbound stops working, and when higher doses might arrive.

1. 0:00 Zepbound effectiveness
2. 2:30 Chronic treatment importance
3. 4:06 Managing expectations
4. 4:38 Future higher doses

• Doses mentioned: 15 mg
• Who is speaking: News or media

In this interview on the On the Pen podcast, host Dave Napman talks with Jeff Cook, who the host introduces as the CEO of Noom. Cook first describes attending a White House event where Noom signed a pledge, led by CMS, on health data portability and access.

1. 0:00 Introduction to Noom
2. 1:26 White House data pledge
3. 7:25 Modernizing health records
4. 12:12 Microdosing GLP-1 program
5. 18:29 Clinical studies vs real world
6. 25:13 Data-driven habit building
7. 30:48 Future of GLP-1 treatments
8. 36:20 Tapering protocols

• Doses mentioned: 2.4 mg, 5 mg and 15 mg
• Who is speaking: News or media

According to the video, the host of On The Pen GLP-1 News says Eli Lilly CEO Dave Ricks told Bloomberg from the Paris Olympics that Lilly intends to report Zepbound as no longer in shortage to the FDA.

1. 0:00 Intro
2. 0:50 FDA Shortage
3. 8:00 Commentary
4. 12:00 Outro

• Who is speaking: News or media

In this live stream from On The Pen, host Dave Knapp says patients taking compounded GLP-1 medications have had no clear way to learn where the active pharmaceutical ingredient (API) in their drug comes from.

1. 0:00 Introduction to compounds
2. 1:14 The problem with API sources
3. 3:14 FDA report on API enforcement
4. 6:17 Freedom of Information Request
5. 9:12 The redaction of API suppliers
6. 11:09 Taking action for patient safety
7. 16:38 Final thoughts and outro

• Prices mentioned: $500 a month
• Who is speaking: News or media

A news or media piece talks about stopping a GLP-1 and what came after. Also covers food noise and cravings.

• Who is speaking: News or media

A news or media piece explains how Zepbound works and what the evidence says. It has no captions we could read, so this is drawn from its title and description.

• Who is speaking: News or media

In this weekly podcast episode from May 13, 2025, host Dave Knap covers a new executive order on prescription drug pricing and CVS Caremark's move to prefer Wegovy over Zepbound.

1. 0:00 Welcome and show introduction
2. 5:08 Analyzing the executive order
3. 19:18 CVS Caremark policy updates
4. 21:54 Interview with Joe Zucchi
5. 35:54 Actionable steps for patients

• Doses mentioned: 2.4 mg, 2.5 mg, 5 mg and 15 mg
• Side effects mentioned: nausea
• Prices mentioned: $499 a month
• Who is speaking: News or media

This episode of On The Pen is part two of a three-part series on compounded tirzepatide.

1. 0:00 Welcome and housekeeping
2. 2:37 Maintenance minute segment
3. 8:04 Addressing recent industry news
4. 12:48 Debunking recent media claims
5. 17:02 Introduction of special guest
6. 19:22 Interview with Scott Bruner
7. 44:03 Importance of local pharmacies
8. 47:03 Semaglutide and future outlook

• Who is speaking: News or media

In this short live stream from the On The Pen GLP-1 News channel, the host goes over two stories from that day. The first is that Novo Nordisk filed lawsuits against several companies, including the telehealth company Amble and, according to the host, BMI MD and possibly others.

1. 0:00 Introduction to the platform
2. 1:06 Novo Nordisk vs. Amble
3. 2:39 Wegovy and Zepbound pricing
4. 4:25 Industry pressures on doctors
5. 6:12 Substack and platform freedom

• Prices mentioned: $500 a month, $200 a month and $349 a month
• Who is speaking: News or media

According to the video, the Zepbound savings card is not delivering the expected savings for some people who have commercial insurance but no coverage for Zepbound. The speaker says these patients expect $564 off at the pharmacy but receive only about $150 off.

• Who is speaking: News or media

A news or media piece talks about stopping a GLP-1 and what came after. It has no captions we could read, so this is drawn from its title and description.

• Who is speaking: News or media

According to the video, food noise is the constant low-level mental chatter about food that many people living with obesity experience, even when they are not hungry.

1. 0:00 Understanding food noise
2. 1:24 The study methodology
3. 2:40 Brain scan results
4. 3:52 Impact on eating habits
5. 5:01 Community stories and conclusion

• Who is speaking: News or media

In this live stream from On The Pen, host Dave Nap covers new CagriSema data for people with type 2 diabetes. He says Novo Nordisk released a 68-week readout in which patients on the high dose lost 15% of their body weight.

1. 0:00 Video introduction
2. 3:02 Medicare coverage update
3. 8:01 Kaggrama data release
4. 10:39 Market and youth usage
5. 13:24 Personal experience and risks
6. 17:31 Hunger management and products
7. 22:53 Future pipeline and wrap up

• Doses mentioned: 15 mg
• Side effects mentioned: fatigue
• Prices mentioned: $50 a month
• Who is speaking: News or media

According to the video, Novo Nordisk is starting a clinical trial that compares its own combination drug against Zepbound (tirzepatide). The narrator says the combination pairs semaglutide, a GLP-1 agonist, with cagrilintide, which is described as an amylin agonist.

• Doses mentioned: 2.4 mg
• Who is speaking: News or media

According to the video, the host uses a kitchen analogy to explain why compounded semaglutide and tirzepatide doses can look so different from one prescription to the next.

• Doses mentioned: 5 mg
• Who is speaking: News or media

The host of On The Pen opens this March 9 live stream with news that Novo Nordisk and Hims & Hers have reached a deal.

1. 0:00 Welcome and news updates
2. 1:04 Novo Nordisk and Hims deal
3. 2:54 Reactions to the partnership
4. 5:54 FDA and compounding industry
5. 8:25 Market dynamics and safety
6. 10:42 Viewer Q&A and upcoming content
7. 12:21 FDA biosimilar regulations
8. 15:44 Side effects and community

• Prices mentioned: $150 a month
• Who is speaking: News or media

The host of On The Pen says a lot happened in the three days before this February 9, 2026 live stream. He recaps the Most Favored Nations announcement, the launch of the Trump Rx website, and the same-day Hims & Hers launch of its own semaglutide pill.

1. 0:00 Industry shakeup overview
2. 4:04 FDA targets compounders
3. 6:11 FDA letters to Novo Nordisk
4. 12:04 Oral versus injectable meds
5. 15:52 Novo Nordisk sues Hims
6. 20:16 Patent fight implications
7. 23:14 Patient empowerment focus
8. 25:46 Bully analogy and ethics

• Doses mentioned: 2.4 mg
• Side effects mentioned: fatigue
• Prices mentioned: $10,000 a month and $200 a month
• Who is speaking: News or media

In this short video from the On The Pen channel, the host, who gives his name as Dave, reacts to newly released clinical trial data on retatrutide from Eli Lilly.

1. 0:00 Intro
2. 1:40 Results
3. 3:25 Weight loss
4. 3:50 Liver

• Who is speaking: News or media

According to the video, the host uses this episode to explain how clinical trial phases work and where Eli Lilly's upcoming weight loss drugs sit within them.

• Who is speaking: News or media